{"organizations": [], "uuid": "9d529bbeddff415a3108f01ee9067247cd72d0d7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "news.morningstar.com", "main_image": "", "site_section": "http://news.morningstar.com/all/dow-jones/technology.aspx", "section_title": "News Archive: Technology", "url": "http://news.morningstar.com/all/dow-jones/technology/2015092510607/exelixis-reports-favorable-trial-results-for-kidney-cancer-drug.aspx", "country": "US", "title": "Exelixis Reports Favorable Trial Results for Kidney Cancer Drug", "performance_score": 0, "site": "morningstar.com", "participants_count": 1, "title_full": "Exelixis Reports Favorable Trial Results for Kidney Cancer Drug", "spam_score": 0.0, "site_type": "news", "published": "2015-09-25T03:00:00.000+03:00", "replies_count": 0, "uuid": "9d529bbeddff415a3108f01ee9067247cd72d0d7"}, "author": "morningstar.com", "url": "http://news.morningstar.com/all/dow-jones/technology/2015092510607/exelixis-reports-favorable-trial-results-for-kidney-cancer-drug.aspx", "ord_in_thread": 0, "title": "Exelixis Reports Favorable Trial Results for Kidney Cancer Drug", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "By Josh Beckerman\nExelixis Inc. provided updated Phase 3 trial results for its kidney cancer drug cabozantinib, which \"significantly improved progression-free survival\" compared with Novartis AG's everolimus, or Afinitor.\nExelixis said in July that cabozantinib met its primary endpoint in the trial, increasing survival.\nThe biopharmaceutical company said Friday that \"treatment with cabozantinib resulted in a strong trend towards improving overall survival.\"\nResults were favorable in the full study population for the primary endpoint analysis as well as a subgroup of patients who had received sunitinb as their only prior VEGF receptor tyrosine kinase inhibitor, the company said.\nShares of Exelixis were up 15% to $6.79 in after-hours trading.\nCabozantinib was granted fast-track designation by the Food and Drug Administration in April, a status that can help speed approval for drugs and vaccines that address serious conditions and unmet medical needs.\nExelixis said it is on track for a New Drug Application filing in the U.S. by the end of 2015, and expects a European filing in early 2016.\nWrite to Josh Beckerman at josh.beckerman@wsj.com\n 25, 2015 19:30 ET (23:30 ", "external_links": ["http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Checked.gif", "http://s7.addthis.com/static/btn/sm-share-en.gif", "http://www.addthis.com/bookmark.php?v=250", "http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Unchecked.gif"], "published": "2015-09-25T03:00:00.000+03:00", "crawled": "2015-09-26T11:47:31.019+03:00", "highlightTitle": ""}